Hypocalcemia News and Research

RSS
Study explores advantages of minimally invasive parathyroidectomy for treating hyperparathyroidism

Study explores advantages of minimally invasive parathyroidectomy for treating hyperparathyroidism

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Chelation therapy with drug disodium EDTA reduces risk of heart attack

Chelation therapy with drug disodium EDTA reduces risk of heart attack

Study: Controversial treatment for autism spectrum disorder may be harmful

Study: Controversial treatment for autism spectrum disorder may be harmful

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

EC grants European market authorization for Revestive to treat short bowel syndrome

EC grants European market authorization for Revestive to treat short bowel syndrome

FDA committee to review NPS’ Gattex NDA in October

FDA committee to review NPS’ Gattex NDA in October

FDA extends PDUFA action date for NPS Gattex NDA

FDA extends PDUFA action date for NPS Gattex NDA

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Gattex may represent new treatment approach for short bowel syndrome

Gattex may represent new treatment approach for short bowel syndrome

NPS first quarter net loss increases to $10.6 million

NPS first quarter net loss increases to $10.6 million

FDA issues Complete Response Letter to Amgen’s sBLA for XGEVA

FDA issues Complete Response Letter to Amgen’s sBLA for XGEVA